• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Plasma Exchange to Reduce Biological Age

June 4, 2025

Therapeutic plasma exchange (TPE) separates, removes and replaces a patient’s plasma with donor plasma and is commonly used for patients with antibody mediated rejection of allograft organs or autoimmune conditions.  Since metabolites increase with age, researchers at Circulate Health and the Buck Institute for Aging explored the effects of plasma exchange on biological age. Many factors affect biological age, and the most accurate methods to calculate it include DNA methylation patterns combined with machine learning algorithms. In a small, exploratory randomized clinical trial to determine if TPE affects biological age, researchers randomized 42 patients over 60 years of age to receive either saline placebo, TPE one time per month for six months, or TPE or TPE plus intravenous injections of immunoglobin (IVIG) two times once a week each month for three months. Baseline and two longitudinal blood samples were collected during the study, and biological age was calculated using data from the patients’ clinical laboratory values, epigenomic, transcriptomic, proteomic, and metabolomic profiles. TPE was relatively safe (two patients experienced adverse reactions). After adjusting biological age for known covariates, researchers determined that patients who received TPE and IVIG had the greatest reduction in biological age at the one-month mark—2.6 years compared to the placebo group—and the greatest changes in multi-omic profiling, including changes in cellular and molecular responses, increased immune responses, modulation of proteins associated with chronic inflammation, and increased cellular senescence. Larger and longer studies are needed to better define the effect of TPE and IVIG on biological age.

Reference:

Fuentealba M, Kiprov D, Schneider K, Mu W-C,  at al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Aging Cell 2025 e70103

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Cell-Based Therapies and Treatment of Cardiac Disease

  • Restrictive Platelet Transfusions Superior in Preterm Infants with Thrombocytopenia

  • Cost-Effectiveness of Transfusions to Prevent Silent Cerebral Infarcts in Children with Sickle Cell Disease

Show Comments

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Exchange to Reduce Biological Age

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley